- Home
- KNSL vs EXAS Comparison
KNSL vs EXAS Comparison
Compare KNSL & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSL
- EXAS
- Stock Information
- Founded
- KNSL 2009
- EXAS 1995
- Country
- KNSL United States
- EXAS United States
- Employees
- KNSL N/A
- EXAS N/A
- Industry
- KNSL Property-Casualty Insurers
- EXAS Medical Specialities
- Sector
- KNSL Finance
- EXAS Health Care
- Exchange
- KNSL Nasdaq
- EXAS Nasdaq
- Market Cap
- KNSL 11.0B
- EXAS 10.7B
- IPO Year
- KNSL 2016
- EXAS N/A
- Fundamental
- Price
- KNSL $486.88
- EXAS $51.91
- Analyst Decision
- KNSL Buy
- EXAS Strong Buy
- Analyst Count
- KNSL 10
- EXAS 20
- Target Price
- KNSL $491.88
- EXAS $70.26
- AVG Volume (30 Days)
- KNSL 227.0K
- EXAS 2.8M
- Earning Date
- KNSL 07-24-2025
- EXAS 07-30-2025
- Dividend Yield
- KNSL 0.14%
- EXAS N/A
- EPS Growth
- KNSL 15.35
- EXAS N/A
- EPS
- KNSL 17.37
- EXAS N/A
- Revenue
- KNSL $1,638,131,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- KNSL $12.94
- EXAS $14.58
- Revenue Next Year
- KNSL $12.99
- EXAS $12.75
- P/E Ratio
- KNSL $27.62
- EXAS N/A
- Revenue Growth
- KNSL 22.79
- EXAS 11.57
- 52 Week Low
- KNSL $366.92
- EXAS $39.97
- 52 Week High
- KNSL $531.79
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- KNSL 57.87
- EXAS 44.34
- Support Level
- KNSL $481.50
- EXAS $52.00
- Resistance Level
- KNSL $492.15
- EXAS $55.90
- Average True Range (ATR)
- KNSL 10.86
- EXAS 2.31
- MACD
- KNSL 1.19
- EXAS -0.04
- Stochastic Oscillator
- KNSL 80.53
- EXAS 24.90
About KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.